Terms: = Germ cell tumor AND LDH
1087 results:
1. Identification of Plasma Lipid Alterations Associated with Melanoma Metastasis.
Szász I; Koroknai V; Várvölgyi T; Pál L; Szűcs S; Pikó P; Emri G; Janka E; Szabó IL; Ádány R; Balázs M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673837
[TBL] [Abstract] [Full Text] [Related]
2. Astragaloside IV combined with ligustrazine ameliorates abnormal mitochondrial dynamics via Drp1 SUMO/deSUMOylation in cerebral ischemia-reperfusion injury.
Chen X; Yang T; Zhou Y; Mei Z; Zhang W
CNS Neurosci Ther; 2024 Apr; 30(4):e14725. PubMed ID: 38615367
[TBL] [Abstract] [Full Text] [Related]
3. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study.
Py C; De Vito C; Tsantoulis P; Kaya G; Labidi-Galy SI; Dietrich PY
Swiss Med Wkly; 2023 Dec; 153():3504. PubMed ID: 38579317
[TBL] [Abstract] [Full Text] [Related]
4. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
[TBL] [Abstract] [Full Text] [Related]
5. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
[TBL] [Abstract] [Full Text] [Related]
6. Early B cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study.
Hu W; Wang M; Sun G; Zhang L; Lu H
Cell Signal; 2024 Jun; 118():111139. PubMed ID: 38479556
[TBL] [Abstract] [Full Text] [Related]
7. cellular senescence in testicular cancer. Is there a correlation with the preoperative markers and the extent of the tumor? An experimental study.
Tatanis V; Veroutis D; Pantelis P; Theocharous G; Sarlanis H; Georgiou A; Peteinaris A; Natsos A; Moulavasilis N; Kavantzas N; Kotsinas A; Adamakis I
Arch Ital Urol Androl; 2024 Mar; 96(1):12246. PubMed ID: 38441175
[TBL] [Abstract] [Full Text] [Related]
8. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy.
Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
[TBL] [Abstract] [Full Text] [Related]
9. Survival analysis of comprehensive treatment in Chinese patients with metastatic melanoma: A retrospective analysis.
Chen Q; Zhao Y; Li P; Duan J; Fu X; Tang Y; Ma Y; Zhou Q
Skin Res Technol; 2024 Feb; 30(2):e13546. PubMed ID: 38279601
[TBL] [Abstract] [Full Text] [Related]
10. BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JWWB; Hospers GAP; Kapiteijn E; Bloem M; Piersma D; Stevense-den Boer M; Verheijden RJ; van der Veldt AAM; Wouters MWJM; Blokx WAM; Suijkerbuijk KPM
Cancer; 2024 May; 130(9):1673-1683. PubMed ID: 38198485
[TBL] [Abstract] [Full Text] [Related]
11. Apocynin exerts neuroprotective effects in fumonisin b1-induced neurotoxicity via attenuation of oxidative stress and apoptosis in an animal model.
Krishnaswamy K; Manasa V; Khan MT; Serva Peddha M
J Food Sci; 2024 Feb; 89(2):1280-1293. PubMed ID: 38193205
[TBL] [Abstract] [Full Text] [Related]
12. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
13. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG
Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329
[TBL] [Abstract] [Full Text] [Related]
14. Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Richtig E; Nguyen VA; Koelblinger P; Wolf I; Kehrer H; Saxinger W; Ressler JM; Weinlich G; Meyersburg D; Hafner C; Jecel-Grill E; Kofler J; Lange-Asschenfeldt B; Weihsengruber F; Rappersberger K; Svastics N; Gasser K; Seeber A; Kratochvill F; Nagler S; Mraz B; Hoeller C
Melanoma Res; 2024 Apr; 34(2):142-151. PubMed ID: 38092013
[TBL] [Abstract] [Full Text] [Related]
15. A novel lactate dehydrogenase-based risk score model to predict the prognosis of primary central nervous system germ cell tumor treated with chemoradiotherapy.
Yao DC; Ye BK; Yao DJ; Guo CC
Clin Neurol Neurosurg; 2024 Jan; 236():108081. PubMed ID: 38091701
[TBL] [Abstract] [Full Text] [Related]
16. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
[TBL] [Abstract] [Full Text] [Related]
17. Systemic therapy timing and use in patients with advanced melanoma at the end of life: A retrospective cohort study.
van Lith PEA; Schreuder K; Jalving M; Reyners AKL; Been LB; Rácz E; Fransen HP; Louwman MWJ
J Dermatol; 2024 Apr; 51(4):584-591. PubMed ID: 38078557
[TBL] [Abstract] [Full Text] [Related]
18. Potential Protective Effects of Spirulina (
Mallamaci R; Storelli MM; Barbarossa A; Messina G; Valenzano A; Meleleo D
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069399
[No Abstract] [Full Text] [Related]
19. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
[TBL] [Abstract] [Full Text] [Related]
20. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
[TBL] [Abstract] [Full Text] [Related]
[Next]
